Browse Category

Biotechnology 7 October 2025 - 16 October 2025

Iovance shares surge 43% as Amtagvi revenue highlights manufacturing turning point
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close marketbeat.com. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating whether Moderna’s future is bright or bleak. Even after the pop, however, Moderna’s stock is a shadow of its former self: shares have cratered roughly 80% below last year’s levels marketbeat.com and are down one-third in 2025 alone. The once high-flying biotech – which briefly surpassed $170 billion in market value during the COVID vaccine euphoria – is now hovering near multi-year lows, with a market cap around $10–11 billion ts2.tech.
16 October 2025
··
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

With the stock now trading well above $150, investors are debating how much further PRAX could rise. If ulixacaltamide wins approval, analysts believe it could capture a sizable ET market. However, success in neurology trials can be binary – failures or setbacks could send the stock sharply down. Looking ahead, Praxis expects more data by late 2025/early 2026. Management’s guidance has focused on these milestones rather than concrete revenue forecasts, which is typical for clinical-stage biotechsnasdaq.com. In the near term, analysts will scrutinize FDA feedback and the actual content of the trial data. As Reuters summarized, the Phase 3 win “gives hope” for a much-needed new ET therapyreuters.com. Coupled with a healthy cash position and ongoing epilepsy trials, many experts now view Praxis’s prospects more favorably. Still, they caution that valuation is stretched – PRAX’s market cap reflects sky-high expectations that all these programs succeed. As of Oct. 16, 2025, the stock is riding a wave of bullish sentiment, but investors will want hard evidence from regulators and future studies before declaring victoryreuters.comneurologylive.com.
16 October 2025
··
Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology’s stock skyrocketed mid-week after a bold endorsement from a well-known tech investor. On Oct. 15, SANA shares jumped over 25% in a single session, closing at $5.62 ts2.tech. In intraday trading the stock even hit roughly $6.55 before paring back gains ts2.tech. The catalyst? A viral post on social media. Hedge fund manager Eric Jackson — known for spotting high-growth plays — proclaimed on X that “Biotech is back… $SANA looks like the next 100-bagger platform”. He pointed to an improving macro backdrop spurring a rotation “from megacaps to growth” stocks benzinga.com benzinga.com. Jackson’s ultra-bullish tweet injected a burst of momentum into Sana, with Benzinga reporting that the stock soared early Wednesday after his call went public ts2.tech. In fact, trading activity was so frenzied that exchanges halted SANA multiple times for volatility cooling-off periods.
16 October 2025
··
Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Omeros shares were trading around $4–$4.60 through early October, then exploded on Oct. 15. Data from the company’s IR site show OMER jumped from $4.10 to $10.42 by Oct 15 closeinvestor.omeros.com. Intraday on Oct 15, it even hit a high around $12.10. This roughly 150% one-day surge was driven by the Novo Nordisk deal. Trading volume was staggering: Benzinga reports ~89.2 million shares traded during the rallybenzinga.com. By mid-October 16 pre-market, OMER was around $9–10 per share – still far above levels seen just days priorts2.techbenzinga.com.
16 October 2025
···
Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

On Oct. 15, SANA spiked as investors reacted to hedge fund manager Eric Jackson’s bullish call. In a post on X, Jackson proclaimed: “Biotech is back. Rates are falling, inflation is cooling, and money is rotating from megacaps to growth again,” and suggested “$SANA looks like the next 100-Bagger platform”benzinga.com. Benzinga and other outlets noted that this endorsement sent SANA shares up sharply that morningbenzinga.com.
15 October 2025
··
Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion’s stock showed wild swings in early October. On Oct 7, 2025 the shares fell about 5.4% to ~$5.23 amid a broad market slump nasdaq.com. The very next day the stock rebounded sharply, jumping roughly 16% to ~$6.08 ts2.tech. This put RXRX near the middle of its 52-week trading range ts2.tech. Trading volume on these moves was heavy, with tens of millions of shares changing hands as investors positioned for upcoming company news. By Oct 14, RXRX was around $5.89 stocktitan.net.
15 October 2025
···
Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech’s stock skyrocketed this week, delivering eye-popping gains for investors. On Tuesday night, SEED shares surged over 92% in after-hours trading following a flurry of positive developmentsbenzinga.com. The price spiked from the $1.40 range to roughly $2.76 in extended trading – nearly a doubling overnight. By Wednesday Oct. 15, the stock opened sharply higher before paring back to about $1.43 by mid-dayinvesting.com, roughly flat from Tuesday’s official close of $1.44benzinga.com.
15 October 2025
·
Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion’s stock jump in mid-October comes as the company lines up important clinical updates and validates its AI-driven vaccine technology. On Oct 13, Evaxion announced it will present two-year data from its Phase 2 trial of EVX-01 at the ESMO Congress in Berlin globenewswire.com. The October presentation will cover efficacy, immunogenicity, safety, best overall response, and T‑cell response durability of EVX-01 plus Merck’s KEYTRUDA® globenewswire.com. Earlier one-year interim results showed a 69% overall response rate and tumor reduction in 15 of 16 patients globenewswire.com, highlighting the vaccine’s promise. Evaxion’s CSO/Interim CEO Birgitte Rønø emphasized that being selected for an ESMO oral presentation “is a testament to the interest in EVX-01 and the field of personalized cancer vaccines” globenewswire.com.
15 October 2025
···
Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

In-Depth: Arcadia’s stock price has been extremely volatile in October 2025, jumping ~68% pre-market on Oct 15. The rally was sparked by a Trump tweet on China trade and follows mixed Q2 results. In the past few days RKDA’s trading range has widened dramatically. After closing at $3.69 on Oct 14 stockanalysis.com, pre-market Oct 15 it was near $6.22 stockanalysis.com, on very high volume. This wild move came as commodity and agri-tech stocks rallied on geopolitical news.
15 October 2025
···
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex shares have been extremely volatile. After surging over 30% during regular hours on Oct 14, 2025, to about $0.25, the stock jumped another 41% in after-hours trading to roughly $0.36 on the cancer data announcement benzinga.com benzinga.com. That rally brought the stock briefly near its 30-day resistance around $0.26 ainvest.com. Before this spike, GNPX had been trading around $0.20. Over the last five trading days the stock was up about 25.6%, although year‐to‐date it was still down roughly 70% benzinga.com. For context, GNPX’s 52-week high is ~$4.09 and its 52-week low is about $0.22 google.com benzinga.com.
15 October 2025
···
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein in ATTR amyloidosis patients ts2.tech. Today, the company’s focus is on curative gene edits in severe diseases. Its lead programs are NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema ts2.tech ts2.tech. Both use CRISPR delivered via lipid nanoparticles to knock out genes with one dose. Intellia’s partnerships have fueled its pipeline: a 2016 deal with Regeneron co-developed NTLA-2001 ts2.tech, and Regeneron later expanded the alliance to other targets. Other collaborations include AvenCell, Kyverna, ONK Therapeutics and ReCode, which use Intellia’s platform to engineer cell therapies or improve delivery ts2.tech. These alliances help the small company leverage resources while concentrating on its late-stage in-vivo programs. Recent restructuring and discontinuation of a Phase 1 program reflect Intellia’s narrow focus on ATTR and HAE ts2.tech.
9 October 2025
··
AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

After languishing through the summer, Recursion’s share price came to life in early October 2025. By Oct 8 the stock had rebounded to around $6.09 insidermonkey.com, putting it near the middle of its volatile 52-week range ts2.tech. For context, RXRX had traded in the double-digits when AI hype in biotech peaked earlier in the year, then slid into the high-$3s during industry sell-offs ts2.tech. Even after this week’s pop, shares remain ~30% lower than a year ago ts2.tech. Such dramatic swings are not unusual for a pre-revenue biotech stock – especially one at the intersection of two hot themes that can amplify volatility.
9 October 2025
···
Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real?

Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real?

Xenetic’s stock was relatively quiet for most of 2025 until early October, when it suddenly erupted. By Oct 8, 2025, XBIO had skyrocketed to levels not seen in years. On that day alone, the stock soared 123% to $9.58finanzen.ch, after touching intraday highs well above $10. This move extended a remarkable run from under $3.50 at the start of the week to nearly $12-13 intraday on Oct 8ainvest.com. In fact, at one point XBIO was up about +195% in a single session according to real-time trackerstimothysykes.com. Such gains are extraordinary – even by penny stock standards – and placed XBIO among the top percentage gainers across the entire Nasdaq.
8 October 2025
··
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025, the stock closed at $27.34, down roughly 0.7% from $27.54 on the prior sessionstockinvest.us. Technical analysts at Stockinvest.us noted the shares were near the upper part of a wide falling trend and predicted a possible trading range of $26.40–$28.73 on Oct 8, with longer‑term support around $26 and resistance near $31stockinvest.us. While short‑term signals were positive, they cautioned that the overall downward trend remainsstockinvest.us.
8 October 2025
··
Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran, an in‑vivo CRISPR therapy for transthyretin amyloidosis. A GlobeNewswire release reported that a single dose produced a rapid, deep and durable reduction of serum TTR levels—mean reduction 92 % at 24 months and 90 % at 36 monthsglobenewswire.com. Patients also showed clinical improvements or stabilization of neuropathy and cardiac markersglobenewswire.com, and safety findings were mostly mild infusion‑related eventsglobenewswire.com. CEO John Leonard said the data “demonstrate rapid, deep and durable TTR reductions with meaningful clinical improvements” and reiterated plans to complete enrolment in the Phase 3 MAGNITUDE‑2 trial in the first half of 2026globenewswire.comglobenewswire.com.
8 October 2025
··
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior year the share price ranged from $30.04 to $73.95, and year‑to‑date performance stood at +97.5 %. Trading volume on INDmoney’s quote was 3.1 million sharesindmoney.com.
8 October 2025
·
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to develop potential in vivo therapies – treatments delivered directly into the body to edit genes inside patients’ cells. In fact, Intellia reported the first-ever clinical evidence that CRISPR could provide a therapeutic benefit in humans via in-body gene editing, showing in 2021 that a one-time IV infusion could drastically lower a disease-causing protein in patients ts2.tech. This pioneering achievement, accomplished with their transthyretin amyloidosis program, has put Intellia on the map as a trailblazer in genomic medicine.
8 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharmaceuticals, Inc. is redefining drug discovery by combining cutting-edge biology and data science. Based in Salt Lake City, this “TechBio” pioneer uses automation, massive datasets and machine learning to identify new therapies faster than traditional labsdirectorstalkinterviews.comnasdaq.com. Its mission – “to decode biology to radically improve lives” – has attracted major industry partners and bold investors. But as an early-stage biotech with no approved drugs, Recursion’s stock can be a rollercoaster ride, swayed by scientific milestones and market sentiment alike.
8 October 2025
···
No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

Regencell Bioscience is an early-stage biotech company focused on Traditional Chinese Medicine. Headquartered in Causeway Bay, Hong Kong, Regencell researches, develops, and aims to commercialize herbal treatment formulae for neurocognitive disorders – primarily Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder Marketbeat Insidermonkey. The company’s approach is based on the “Sik-Kee Au TCM Brain Theory,” a proprietary herbal methodology developed by the CEO’s father ts2.tech.
7 October 2025
··
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences’ stock chart for 2025 looks like a hockey stick – mostly flat/down all year and then vertical in October. On Monday, Oct 6, SPRB opened around $8.60 and skyrocketed to $130.40 by the close after the FDA news. The 52-week high was shattered in the process. Volume surged into the tens of millions of shares, far exceeding the tiny float, as investors clamored for a piece of the action. The rally continued after hours, and in pre-market trading Tuesday shares jumped almost another 90% at one point.
7 October 2025
··
1 … 17 18 19 20 21
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Constellation Energy

NASDAQ: CEG 95 / 100
#2 BUY

AerCap

NYSE: AER 93 / 100
#3 BUY

Walt Disney

NYSE: DIS 92 / 100
#4 ACCUMULATE

AIG

NYSE: AIG 90 / 100
#5 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.